Search

Search Constraints

You searched for: Author/Creator Berkowitz, Scott D

Search Results

1. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. Issue 14 (21st May 2021)

2. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Issue 9985 (13th June 2015)

3. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Issue 3 (14th April 2020)

4. Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. Issue 5 (July 2016)

5. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. (August 2022)

6. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. (31st August 2021)

7. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. (25th August 2021)

8. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Issue 5 (30th June 2021)

9. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Issue 13 (17th February 2016)

10. Regional, sex, and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial. Issue 1 (January 2021)